drugset / Trial / NCT01327612
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
Timeline
- Start
- 2011-03-03
- Primary completion
- 2020-02-05
- Completion
- 2020-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conatumumab | Monoclonal antibody | — | Intravenous |
| Subject | Ganitumab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Leucovorin | Small molecule | 200 mg/m2 | — |
| Background | Leucovorin | Small molecule | 400 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |